Antimalarial agents: closing the gate on Toll-like receptors? - PubMed (original) (raw)

Editorial

. 2006 Oct;54(10):3068-70.

doi: 10.1002/art.22157.

• PMID: 17009223
• DOI: 10.1002/art.22157

Free article

Editorial

Antimalarial agents: closing the gate on Toll-like receptors?

Robert Lafyatis et al. Arthritis Rheum. 2006 Oct.

Free article

No abstract available

PubMed Disclaimer

Comment on

• Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.
  Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, Francès C, Wechsler B, Huong du LT, Ghillani P, Musset L, Lechat P, Piette JC. Costedoat-Chalumeau N, et al. Arthritis Rheum. 2006 Oct;54(10):3284-90. doi: 10.1002/art.22156. Arthritis Rheum. 2006. PMID: 17009263 Clinical Trial.

Similar articles

• Antimalarial agents and lupus.
  Wallace DJ. Wallace DJ. Rheum Dis Clin North Am. 1994 Feb;20(1):243-63. Rheum Dis Clin North Am. 1994. PMID: 8153401 Review.
• Do Toll-like receptors contribute to the pathogenesis of lupus?
  Youinou P. Youinou P. J Rheumatol. 2007 Aug;34(8):1641-2. J Rheumatol. 2007. PMID: 17696280 No abstract available.
• Effect of antimalarial agents on fasting lipid profile in systemic lupus erythematosus.
  Capell HA. Capell HA. J Rheumatol. 2001 Jul;28(7):1742. J Rheumatol. 2001. PMID: 11469495 No abstract available.
• [Antimalarials in lupus erythematosus treatment].
  Woźniacka A. Woźniacka A. Przegl Lek. 2002;59(3):179-82. Przegl Lek. 2002. PMID: 12184034 Review. Polish.

Cited by

• Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
  Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Rainsford KD, et al. Inflammopharmacology. 2015 Oct;23(5):231-69. doi: 10.1007/s10787-015-0239-y. Epub 2015 Aug 6. Inflammopharmacology. 2015. PMID: 26246395 Review.
• Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac disease.
  Izmirly PM, Buyon JP, Saxena A. Izmirly PM, et al. Curr Opin Rheumatol. 2012 Sep;24(5):466-72. doi: 10.1097/BOR.0b013e328356226b. Curr Opin Rheumatol. 2012. PMID: 22832822 Free PMC article. Review.
• Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage.
  de Moreuil C, Alavi Z, Pasquier E. de Moreuil C, et al. Br J Clin Pharmacol. 2020 Jan;86(1):39-49. doi: 10.1111/bcp.14131. Epub 2019 Dec 17. Br J Clin Pharmacol. 2020. PMID: 31633823 Free PMC article. Review.
• Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.
  Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, Walzer T, François B, Sève P. Jamilloux Y, et al. Autoimmun Rev. 2020 Jul;19(7):102567. doi: 10.1016/j.autrev.2020.102567. Epub 2020 May 4. Autoimmun Rev. 2020. PMID: 32376392 Free PMC article. Review.
• Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.
  Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, Khamashta MA, Kim MY, Saxena A, Friedman D, Llanos C, Piette JC, Buyon JP. Izmirly PM, et al. Circulation. 2012 Jul 3;126(1):76-82. doi: 10.1161/CIRCULATIONAHA.111.089268. Epub 2012 May 24. Circulation. 2012. PMID: 22626746 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information